Homocysteine and nitric oxide levels in plasma of patients with pseudoexfoliation syndrome, pseudoexfoliation glaucoma, and primary open-angle glaucoma

Altıntaş, Özgül; Maral, Hale; Yüksel, Nurşen; Karabaş, V. Levent; Dillioğlugil, Meltem Özlen; Çağlar, Yusuf

doi:10.1007/s00417-004-1097-2

Cited by 81 publications

(59 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We found that serum Hcy level in patients with POAG did not statistically differ from the control group, and this finding is in agreement with previous published works [26,27].…”

Section: Pexg (N=36)supporting

confidence: 93%

Levels of plasma homocysteine in pseudoexfoliation glaucoma

Tranchina

Centofanti

Oddone

et al. 2010

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

Background To examine levels of serum homocysteine (Hcy), vitamin B12 and folic acid in patients with pseudoexfoliation glaucoma (PEXG), primary open-angle glaucoma (POAG), and healthy control subjects. Methods This study included 36 patients with PEXG, 40 with POAG, and 40 age-matched healthy subjects. Fasting plasma Hcy concentrations and levels of serum vitamin B12 and folic acid were measured using competitive chemiluminescent enzyme immunoassay; values exceeding 14 μm/l were considered elevated. Results Mean plasma Hcy was significantly higher in PEXG (16.55±7.23 μm/l) compared with POAG (13.91±3.61 μm/l) and controls (13.12±5.13 μm/l) (p=0.03 and p=0.0007 respectively).There were no statistical differences in serum vitamin B12 and folic acid levels among PEXG, POAG and control subjects (p>0.05). A moderate, although statistically significant, relationship between Hcy and folic acid levels was found in the PEXG group (R 2 =0.23, p=0.003). Hcy levels were found not to be related with folic acid or vitamin B12 in either POAG or control subjects. Conclusions In this study, plasma Hcy is significantly higher in PEXG group than the POAG and control groups. Hyper-Hcy might play a role in the pathogenesis of PEXG. Hyper-Hcy may be an independent factor stressing vasculopathy in addition to pseudoexfoliation, so might be a modifiable risk factor for PEXG.

show abstract

“…We found that serum Hcy level in patients with POAG did not statistically differ from the control group, and this finding is in agreement with previous published works [26,27].…”

Section: Pexg (N=36)supporting

confidence: 93%

Levels of plasma homocysteine in pseudoexfoliation glaucoma

Tranchina

Centofanti

Oddone

et al. 2010

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

show abstract

“…Given the sample size calculations already mentioned, it seems hardly www.intechopen.com surprising some studies have had a negative outcome. In this respect, it is interesting to note that 3 of 5 studies reporting no significant association actually demonstrated small 78 or considerable 74,81 differences in plasma homocysteine between POAG and control. This is confounded by large variance in the population (as shown by standard deviation) and high mean plasma homocysteine in controls.…”

Section: Authormentioning

confidence: 96%

Homocysteine in the Pathogenesis of Chronic Glaucoma

Kadhim¹,

Clement²

2011

The Mystery of Glaucoma

View full text Add to dashboard Cite

“…Structural vascular abnormalities documented in eyes with exfoliation syndrome could be involved [76][77][78]. Hyperhomocysteinemia which is a major risk factor for vascular diseases, including venous thrombosis, was reported to be more common in exfoliation syndrome and exfoliation OAG patients than in healthy controls in several studies [79][80][81][82].…”

Section: Retinal Vein Occlusion As Risk Factor For Open Angle Glaucomamentioning

confidence: 99%

Diabetes Mellitus and Retinal Vein Occlusion as Risk Factors for Open Angle Glaucoma and Neuroprotective Therapies for Retinal Ganglion Cell Neuropathy

Bikbova¹,

Oshitari²,

Yamamoto³

2011

J Clin Exp Ophthalmol

View full text Add to dashboard Cite

of glaucoma (NTG), and the prevalence of NTG is 3.6% in patients >40-years-of-age in Japan [10]. The average intraocular pressure (IOP) in patients with POAG is 15.4 ± 2.8 mmHg, which is significantly higher than that of normal subjects (14.5 ± 2.5 mmHg) [1][2][3][4][5][6][7][8][9][10] even though the average difference in the IOP is only 0.9 mmHg. Thus, a reduction of the IOP the standard therapy for glaucoma may not be sufficient for the complete management of the patients with glaucoma in Japan. Other therapeutic modalities, such as neuroprotection, should be considered for a complete therapeutic regimen for glaucoma patients.RGC death and axonal degeneration are most likely involved in the progression of DR, RVO, and glaucoma. Many neuroprotective therapies that prevent RGC death and axonal degeneration have been and are being investigated, and some of these neuroprotective factors may be used clinically in the near future. To establish neuroprotective therapies for DR, RVO and glaucoma, a determination of the exact mechanism that leads to a progression of RGC neuropathy to death and axonal degeneration is required [11]. However, the pathogenesis of the onset and progression of RGC neuropathy has still not been definitively determined. Identification of the risk factors for the onset and the progression of disease would help in determining the Abstract Glaucoma, diabetic retinopathy (DR), and retinal vein occlusion (RVO) are major diseases that can lead to blindness and affect mainly the elderly population worldwide. The results of recent investigations have demonstrated that the death of retinal ganglion cells (RGCs) and their axons is the common pathological change in these three disease processes. The exact mechanism that is responsible for the onset and progression of RGC death and axonal degeneration in patients with glaucoma, DR and RVO has not been definitively determined. Thus, identifying the risk factors for the onset and the progression of RGC neuropathy can help in deciding not only the specific treatments but also whether the treatments should be initiated, withheld, or augmented in individuals with glaucoma, DR, and RVO. This review describes the major risk factors for the onset of glaucoma, and the factors associated with the progression of glaucoma that have been obtained from large population-based prevalence and incidence studies. In addition, the potential risk factors for glaucoma, diabetes mellitus, and RVO are discussed in terms of the results obtained by both clinical and laboratory studies. This review introduces potential neuroprotective therapies for damaged RGC in eyes with RGC neuropathy, and the factors that should be considered for a complete therapy for the RGC neuropathy involved in glaucoma, DR and RVO. Neuroprotective therapies combined with a reduction of the IOP should be considered for the complete management of RGC neuropathy involved in glaucoma,

show abstract

Homocysteine and nitric oxide levels in plasma of patients with pseudoexfoliation syndrome, pseudoexfoliation glaucoma, and primary open-angle glaucoma

Cited by 81 publications

References 47 publications

Levels of plasma homocysteine in pseudoexfoliation glaucoma

Levels of plasma homocysteine in pseudoexfoliation glaucoma

Homocysteine in the Pathogenesis of Chronic Glaucoma

Diabetes Mellitus and Retinal Vein Occlusion as Risk Factors for Open Angle Glaucoma and Neuroprotective Therapies for Retinal Ganglion Cell Neuropathy

Contact Info

Product

Resources

About